Medtronic made waves in 2013 by moving beyond devices; Solona wins FDA clearance for a new orthopedic implant;

@FierceMedDev: Baxter nails a CE mark for next-generation home hemodialysis. More | Follow @FierceMedDev

@MarkHFierce: More problems for 23andMe--two women are suing the company over its test claims. Article | Follow @MarkHFierce

@MichaelGFierce: 'Walking' DNA motor on nanotube tracks could someday deliver drugs. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: FDA approves Philips' spectrometry for dense breasts in cancer screenings. Story | Follow @GalenMoore

> Medtronic ($MDT) is noted as having made waves in 2013 for being one of the first medical device companies to try to move beyond medical devices and more actively into healthcare services. Story

> Solona Surgical gained FDA clearance for a new implant that orthopedic and podiatric surgeons can use in foot and ankle procedures, and a rollout is planned for the 2014 first quarter. Item

> Reverse Medical obtained a CE mark to start marketing its Barrel vascular reconstruction device in Europe. Item

> Expectations are that major CMS reimbursement cuts are on their way for image-guided breast biopsies and other medical imaging options, and the fear is that patient outcomes will be harmed as a result. Story

Biotech News

@FierceBiotech: The 5 biggest trends in biopharma R&D in 2013. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: J&J partners up with Orion on a new approach to fighting Alzheimer's--neurotransmitters--a la Lundbeck/Otsuka. News | Follow @JohnCFierce

@DamianFierce: Welcome back, Iclusig. Release | Follow @DamianFierce

@EmilyMFierce: Cells from the eye are inkjet printed for the first time. More | Follow @EmilyMFierce

> Ariad storms back with an FDA nod to get Iclusig back on the U.S. market. Story

> GlycoMimetics gets back on the IPO train with another pitch. More

> Jazz Pharma trades $1B for Gentium and a well-traveled orphan drug. News

Pharma News

@FiercePharma: Top new news Thursday: Bristol bails out of diabetes venture in $4.1B sell-out to AstraZeneca. More | Follow @FiercePharma

@EricPFierce: FDA still has to approve J&J plans to lease part of Ben Venue plant and make Doxil itself. Article | Follow @EricPFierce

@CarlyHFierce: Bad news for AstraZeneca. Appeals court frees Hanmi of double-damage risk for its Nexium copy. Story | Follow @CarlyHFierce

> Actelion will pay $407M in damages for its buyout to protect Tracleer. News

> Jazz will pay $1B for Italy's Gentium, sweeping up another specialty drugmaker. Story

> Doxil update: J&J strikes deal to manufacture Doxil itself at Ben Venue plant. More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.